Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program.

Personalized medicine - 1 May 2017

Reynolds Kristen K, Pierce Deanne L, Weitendorf Frederick, Linder Mark W

Abstract excerpt

AIM: Determine the ability of a pharmacogenetic service, PRIMER, to identify drug-gene (DGI) and drug-drug interactions (DDI) in patients across multiple conditions. PRIMER consists of patient selection criteria, a gene panel and actionable guidance for DGIs and DDIs. RESULTS: The average patient was prescribed 12 medications. PRIMER identified significant DGIs in 73% of patients tested, with 43% having more than...

Topics

Join the communities discussing this publication.

Drug Interactions
Drug-Related Side Effects and Adverse Reactions
Genetic Testing
Pharmacogenetics
Physicians

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Precision Medicine

Surveys and Questionnaires

Source

Identifiers

PMID: 29767587
DOI: 10.2217/pme-2016-0095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program.PMID 29767587Read ↗

Experience with comprehensive pharmacogenomic multi-gene panel in clinical practice: a retrospective single-center study.Semantic proximity Read ↗

Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.Semantic proximity Read ↗

Disease-drug database for pharmacogenomic-based prescribing.Semantic proximity Read ↗

CLINICAL OPPORTUNITIES FOR GERMLINE PHARMACOGENETICS AND MANAGEMENT OF DRUG-DRUG INTERACTIONS IN PATIENTS WITH ADVANCED SOLID CANCERSSemantic proximity Read ↗

Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid CancersSemantic proximity Read ↗

CLINICAL IMPLEMENTATION OF PREEMPTIVE PHARMACOGENOMICS TESTING FOR PERSONALIZED MEDICINE AT AN ACADEMIC MEDICAL CENTERSemantic proximity Read ↗

Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settingsSemantic proximity Read ↗

Estimating the prevalence of potential and actionable drug-gene interactions in Irish primary care: a cross-sectional studySemantic proximity Read ↗

How to Transition from Single‐Gene Pharmacogenetic Testing to Preemptive Panel‐Based Testing: A TutorialSemantic proximity Read ↗

Defining the Opportunity for Pharmacogenetic Intervention in Primary CareSemantic proximity Read ↗

Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.Semantic proximity Read ↗

Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.